110 related articles for article (PubMed ID: 12778485)
21. Allergenic characterization of new mutant forms of Pru p 3 as new immunotherapy vaccines.
Gómez-Casado C; Garrido-Arandia M; Gamboa P; Blanca-López N; Canto G; Varela J; Cuesta-Herranz J; Pacios LF; Díaz-Perales A; Tordesillas L
Clin Dev Immunol; 2013; 2013():385615. PubMed ID: 24324505
[TBL] [Abstract][Full Text] [Related]
22. Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches.
Valenta R; Campana R; Marth K; van Hage M
J Intern Med; 2012 Aug; 272(2):144-57. PubMed ID: 22640224
[TBL] [Abstract][Full Text] [Related]
23. Sensitization prevalence, antibody cross-reactivity and immunogenic peptide profile of Api g 2, the non-specific lipid transfer protein 1 of celery.
Gadermaier G; Hauser M; Egger M; Ferrara R; Briza P; Santos KS; Zennaro D; Girbl T; Zuidmeer-Jongejan L; Mari A; Ferreira F
PLoS One; 2011; 6(8):e24150. PubMed ID: 21897872
[TBL] [Abstract][Full Text] [Related]
24. Uptake and presentation of exogenous antigen and presentation of endogenously produced antigen by skin dendritic cells represent equivalent pathways for the priming of cellular immune responses following biolistic DNA immunization.
Sudowe S; Dominitzki S; Montermann E; Bros M; Grabbe S; Reske-Kunz AB
Immunology; 2009 Sep; 128(1 Suppl):e193-205. PubMed ID: 18800984
[TBL] [Abstract][Full Text] [Related]
25. Human dendritic cells transfected with allergen-DNA stimulate specific immunoglobulin G4 but not specific immunoglobulin E production of autologous B cells from atopic individuals in vitro.
König B; Petersen A; Bellinghausen I; Böttcher I; Becker WM; Knop J; Saloga J
Immunology; 2007 Oct; 122(2):239-46. PubMed ID: 17848164
[TBL] [Abstract][Full Text] [Related]
26. [Genetic immunization: new ways for protective and therapeutic vaccines against allergic diseases].
Scheiblhofer S; Weiss R; Thalhamer J
Wien Med Wochenschr; 2007; 157(5-6):111-5. PubMed ID: 17427007
[TBL] [Abstract][Full Text] [Related]
27. Genetically engineered vaccines.
Thomas WR; Hales BJ; Smith WA
Curr Allergy Asthma Rep; 2005 May; 5(3):197-203. PubMed ID: 15842957
[TBL] [Abstract][Full Text] [Related]
28. Humoral immune responses to recombinant tree pollen allergens (Bet v I and Bet v II) in mice: construction of a live oral allergy vaccine.
Vrtala S; Grote M; Ferreira F; Susani M; Stocker B; Kraft D; Valenta R
Int Arch Allergy Immunol; 1995; 107(1-3):290-4. PubMed ID: 7613152
[TBL] [Abstract][Full Text] [Related]
29. Genetic engineering of pollen allergens for hayfever immunotherapy.
Bhalla PL
Expert Rev Vaccines; 2003 Feb; 2(1):75-84. PubMed ID: 12901599
[TBL] [Abstract][Full Text] [Related]
30. Nonallergic individuals recognize the same T cell epitopes of Bet v 1, the major birch pollen allergen, as atopic patients.
Ebner C; Schenk S; Najafian N; Siemann U; Steiner R; Fischer GW; Hoffmann K; Szépfalusi Z; Scheiner O; Kraft D
J Immunol; 1995 Feb; 154(4):1932-40. PubMed ID: 7530747
[TBL] [Abstract][Full Text] [Related]
31. Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001.
Smole U; Balazs N; Hoffmann-Sommergruber K; Radauer C; Hafner C; Wallner M; Ferreira F; Grössinger R; de Jong EC; Wagner S; Breiteneder H
Immunobiology; 2010 Nov; 215(11):903-9. PubMed ID: 20005001
[TBL] [Abstract][Full Text] [Related]
32. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1.
Gafvelin G; Thunberg S; Kronqvist M; Grönlund H; Grönneberg R; Troye-Blomberg M; Akdis M; Fiebig H; Purohit A; Horak F; Reisinger J; Niederberger V; Akdis CA; Cromwell O; Pauli G; Valenta R; van Hage M
Int Arch Allergy Immunol; 2005 Sep; 138(1):59-66. PubMed ID: 16103688
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v 1a.
Hartl A; Hochreiter R; Stepanoska T; Ferreira F; Thalhamer J
Allergy; 2004 Jan; 59(1):65-73. PubMed ID: 14674936
[TBL] [Abstract][Full Text] [Related]
34. T cell epitope-containing hypoallergenic recombinant fragments of the major birch pollen allergen, Bet v 1, induce blocking antibodies.
Vrtala S; Akdis CA; Budak F; Akdis M; Blaser K; Kraft D; Valenta R
J Immunol; 2000 Dec; 165(11):6653-9. PubMed ID: 11086111
[TBL] [Abstract][Full Text] [Related]
35. Prevention of allergen-specific IgE production and suppression of an established Th2-type response by immunization with DNA encoding hypoallergenic allergen derivatives of Bet v 1, the major birch-pollen allergen.
Hochreiter R; Stepanoska T; Ferreira F; Valenta R; Vrtala S; Thalhamer J; Hartl A
Eur J Immunol; 2003 Jun; 33(6):1667-76. PubMed ID: 12778485
[TBL] [Abstract][Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
